<DOC>
	<DOC>NCT01560403</DOC>
	<brief_summary>This study is a 1-year open label extension study to collect long term efficacy and safety data from patients who have completed approximately 2 years of dosing in Study CL0600-021.</brief_summary>
	<brief_title>A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021</brief_title>
	<detailed_description>This study served as a 1-year extension study for those US patients who have completed the CL0600-021 study.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<criteria>At completion of Study CL0600021, subjects will be invited to participate in this trial if they meet the following criteria: 1. Completion of the 24month study, CL0600021, regardless if fully weaned from PN/I.V. support 2. Signed and dated informed consent form (ICF) to participate before any studyrelated procedures of Study TEDC11001 are performed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Short bowel syndrome</keyword>
	<keyword>Parenteral nutrition</keyword>
	<keyword>PN</keyword>
	<keyword>HPN</keyword>
	<keyword>TPN</keyword>
	<keyword>SBS</keyword>
</DOC>